Bavarian Nordic A/S
BAVA
Classificação em ações
#5045
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in... Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
Preço da ação
$37.76
Valor de mercado
$2.87B
Variação (1 dia)
0.00%
Variação (1 ano)
1.44%
País
DK
Negociar Bavarian Nordic A/S (BAVA)
Categoria
Healthcare
EPS de Bavarian Nordic A/S (BAVA)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Bavarian Nordic A/S, o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Bavarian Nordic A/S de 2026 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|